GlassScriptPhysician profile
Joseph Liberman
NPI 1871532069
$9,495.09
in general payments reported to CMS, 2019-2025
41 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $1,634 · 2021: $1,700 · 2022: $1,404 · 2023: $1,358 · 2024: $1,015 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,935.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,051.94 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $1,002.10 | 2019-2025 | |
| Abbvie INC. | $935.41 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $891.70 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $749.79 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $487.40 | 2023-2024 | Aptiom |
| Genzyme Corporation | $428.77 | 2019-2023 | |
| Ucb, INC. | $405.12 | 2019-2023 | Nayzilam |
| Lilly USA, LLC | $387.12 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Celgene Corporation | $304.60 | 2021-2023 | Zeposia |
| Genentech USA, INC. | $292.38 | 2021-2024 | Ocrevus |
| Revance Therapeutics, INC. | $289.65 | 2024-2025 | Daxxify |
| Emd Serono, INC. | $271.24 | 2019-2021 | |
| Eisai INC. | $227.19 | 2022-2024 | |
| Amgen INC. | $185.07 | 2021-2025 | Uplizna, Aimovig |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Liberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.